Dario Dornbierer is a pharmaceutical scientist (ETH Zurich), Swiss Federal pharmacist and clinical psychopharmacologist who specialises in drug development in mental health.
After a residency year in a Swiss pharmacy, Dario conducted a PhD in the field of clinical psychopharmacology at the Psychiatric University Hospital in Zurich, where he investigated the antidepressant potential of several drug candidates, applying state-of-the-art neuroscientific methods (EEG, MRI, etc.). With a special focus on sleep pharmacology, he investigated the ability of several compounds to promote deep sleep and improve overall sleeping and waking functions.
In his role as CSO and Board Member at B・SYNC ON parent company, Galventa, Dario is responsible for all aspects related to pharmaceutical technology, clinical sciences and innovation.
Says Dario, “I’m passionate about the intricate interplay between the brain and the mind and how chemical substances can dramatically change the way we perceive the outer and inner world. As a pharmacist, I find it exciting to apply cutting-edge pharmaceutical technologies to the fields of psychopharmacology to improve the safety, tolerability and efficacy of products, thus addressing the urgent unmet clinical need in mental health.”
Dario was granted two entrepreneurial postdoc fellowships to advance his innovative work towards marketable products. He has co-founded two biotech startups focused on mental health and sleep.
Dario is passionate about spending time with his wife and two kids, gardening and playing various instruments.
